Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
Femasys Inc. (NASDAQ:FEMY), a micro-cap healthcare company with a market capitalization of $28.75 million and current stock price of $0.88, announced it received a notification from The Nasdaq Stock Market on Wednesday stating that the company is not in compliance with Nasdaq Listing Rule 5550(a)(2). According to InvestingPro data, the stock has declined about 15% over the past six months. The rule requires listed companies to maintain a minimum bid price of $1.00 per share for their common stock. According to the notice, Femasys’ common stock had a closing bid price below $1.00 per share for 30 consecutive business days.
The notification does not have an immediate effect on the listing or trading of Femasys’ common stock on the Nasdaq Capital Market. The company has been granted a 180-calendar day grace period, ending January 12, 2026, to regain compliance with the minimum bid price requirement. To achieve compliance, the closing bid price of the company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the grace period.
If Femasys does not regain compliance by January 12, 2026, it may be eligible for an additional 180-calendar day compliance period, provided it meets all other initial listing standards for the Nasdaq Capital Market except the minimum bid price rule and notifies Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split. InvestingPro analysis indicates the company is currently burning through cash with negative free cash flow, while operating with a moderate debt level. If the company fails to meet the requirement by the end of the applicable compliance period, its common stock will be subject to delisting from Nasdaq.
Femasys stated that it intends to monitor the closing bid price of its common stock and may consider options to regain compliance, including a reverse stock split if appropriate. The company noted there is no assurance that it will be able to regain compliance with the minimum bid price requirement or other Nasdaq listing rules.
This information is based on a press release statement contained in a Form 8-K filed with the Securities and Exchange Commission. With the company’s next earnings report due on August 6, 2025, investors should note that analyst price targets range from $3 to $12, significantly above current levels. InvestingPro subscribers have access to 8 additional key insights about Femasys, including detailed financial health metrics and growth projections.
In other recent news, Femasys Inc. announced that its FemBloc System received CE Mark certification under European Union Medical (TASE:BLWV) Device Regulation for permanent birth control. This certification allows Femasys to market the FemBloc System across the European Economic Area, with plans to target key markets in Spain, France, Italy, and Germany. H.C. Wainwright maintained its Buy rating on Femasys, highlighting the potential for early sales in Europe before FDA approval in the U.S. Additionally, the company appointed Kelley Nicholas as Chief Commercial Officer to lead commercial strategy and drive revenue growth. Femasys also announced the pricing of a public stock offering and a concurrent private placement, expected to raise around $4.5 million for expanding commercial efforts and product development. The company faces a potential delisting from Nasdaq due to not meeting the minimum Market Value of Listed Securities requirement, with a deadline to regain compliance by November 17, 2025. Femasys is actively monitoring its market value and exploring options to meet Nasdaq’s requirements. These developments are part of Femasys’ ongoing efforts to expand its presence in the women’s health market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.